CytoMed Therapeutics (GDTC) Retained Earnings (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Retained Earnings for 5 consecutive years, with -$14.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 30.15% to -$14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.5 million through Dec 2025, down 30.15% year-over-year, with the annual reading at $60870.0 for FY2025, 100.56% up from the prior year.
  • Retained Earnings hit -$14.5 million in Q4 2025 for CytoMed Therapeutics, down from -$11.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$3.7 million in Q4 2021 to a low of -$14.5 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$8.9 million across 5 years, with a median of -$9.1 million in 2023.
  • Biggest five-year swings in Retained Earnings: crashed 58.21% in 2022 and later dropped 22.21% in 2024.
  • Year by year, Retained Earnings stood at -$3.7 million in 2021, then plummeted by 58.21% to -$5.9 million in 2022, then crashed by 54.61% to -$9.1 million in 2023, then fell by 22.21% to -$11.2 million in 2024, then crashed by 30.15% to -$14.5 million in 2025.
  • Business Quant data shows Retained Earnings for GDTC at -$14.5 million in Q4 2025, -$11.2 million in Q4 2024, and -$9.1 million in Q4 2023.